Longeviti
Breakthrough in Neurotechnology-Longeviti Cranial Implants Gaining Momentum

Longeviti Neuro Solutions is a Baltimore based neurotechnology company with a focus on innovative surgical solutions for complex brain surgeries. From a garage dream three years ago, to becoming a global distributor of multiple neurosurgical products, Longeviti has come a long way in a very short amount of time and continues to gain global recognition.

The company was co-founded in 2016 by Jesse Christopher, a medical device industry executive with more than 15 years of industry-leading management, sales, and marketing experience; and Dr. Chad Gordon, Associate Professor at Johns Hopkins University, and Chief and Fellowship Director of Neuroplastic and Reconstructive Surgery. The team, that was assembled by Christopher in three-short years, has been successful bringing two FDA-cleared neurosurgical implants to market, has 25 patents in various stages of approval, and is the first company to offer neurosurgical implants that address the complex clinical need, “Where can we safely implant this neurotechnology?”

Longeviti will be the first company to offer implants that both restore cranial shape to normalcy while housing functional implant therapies such as stimulation, drainage (shunts), and monitoring. The company’s collaboration with Johns Hopkins Hospital and Johns Hopkins University provides Longeviti with key market advantages, including working with its new discipline of neuroplastic surgery towards commercial innovations. Neuroplastic surgery was created to specifically address growing global unmet neurosurgical needs.

“In the not too distant past, when patients contemplated undergoing neurosurgery, they often were more concerned about their survival than potential deformities, scars, lumps, or bumps left behind after the surgery,” said Christopher. “Now that outcomes are improving, patients are more confident in their chances of making it through surgery to remove tumors, relieve swelling, or implant medical devices, but they also have additional priorities—they want to look the way they did prior to the surgery.”

InvisiShunt’s innovative design and placement capabilities restore the natural contour of patients’ craniums without any cosmetic abnormalities. Because InvisiShunt is an off-the-shelf product, surgeons do not require CT scan data of a patient’s skull to implement it. They can safely and easily augment the device during a complicated surgery. “According to a survey of 562 Hydrocephalus patients conducted by Johns Hopkins, over 72 percent of neurosurgical patients experience pain with their shunt. Up until now, this was an undocumented issue. InvisiShunt is the solution to this and many other problems,” said Christopher.

According to Christopher, Longeviti is uniquely positioned in the marketplace for implant accommodation (a Longeviti term for finding anatomical space for batteries, pumps, and other vital hardware) for neurological disorders.

Our goal is to have the most comprehensive and innovative neurotechnology portfolio in the country, if not the world

“We seem to be the only company thinking about where to put this technology,” said Christopher.

Longeviti’s InvisiShunt has helped numerous patients lead a higher quality of life after complex neurosurgery. Christopher recalls the case of a Hydrocephalus patient who went through nine revision surgeries that ultimately reduced the vascularity of the patient’s skin. Consequently, it became almost impossible to close the wound. Coming to the rescue was the company’s InvisiShunt that helped surgeons successfully carry out the procedure. Today, the patient is fit and leading a comfortable life without facing any post-surgery complication.

Longeviti’s areas of expertise and continued focus include functional neurosurgery, neuro reconstruction, neuromodulation, and neuroplastic surgery. Longeviti’s team collaborates closely with industry and academia to address growing unmet complex neurosurgical needs. Longeviti’s competitive strengths lie in its ability to identify, validate, develop, expedite, and sell proprietary neurosurgical devices. The company identified several unmet clinical needs for complex brain surgeries that no other current company can address singularly.



Christopher explained that although the company’s two products, the InvisiShunt and ClearFit address immediate clinical needs, they also form the platform for future neurosurgical implantable technology. The technique of using the cranial space for replacing bone with bio-compatible material that contains embedded smart wireless technology will not only benefit the urgent clinical needs of today but will lead to neurological enhancements in the not-too-distant future.

The company’s unique products are powered by its team of neurosurgeons, plastic surgeons, and biomechanical engineers with extensive knowledge of the ever-evolving medical space. Longeviti is also working on many advanced technologies, including wireless brain mapping, to further drive the efficiency of its products and help speed up the process of diagnosing and treating diseases. Going beyond the U.S., the company has already started receiving international attention and has recently made its first sale in Saudi Arabia and Israel. Moving forward, Longeviti plans to introduce at least one product every year until 2025. “Our goal is to have the most comprehensive and innovative neurotechnology portfolio in the country, if not the world,” says Christopher.